|
|
|
40
|
05415
|
BLEOMYCIN SULPHATE 15MG INJ (CIP/AHI)
|
BLEOMYCIN SULPHATE
|
BLEOMYCIN SULPHATE
|
15MG VIAL
|
BQ
|
44.85
|
44.85
|
INJECTION
|
0
|
VIAL
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
0884AJ
|
ASTHALIN 5MG/ML RESP SOL (CIP/AHI) SALBUTAMOL
|
SALBUTAMOL
|
ASTHALIN
|
15ML
|
A
|
2.91
|
2.91
|
RESPIRATORY
|
20
|
BOTT
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
48120412
|
SELECTIVE BETA2 ADRENERGIC AGONIST (RESPIRATORY)
|
2022-04-01
|
2024-03-31
|
|
INHALATION
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
0884AJ
|
ASTHALIN 5MG/ML RESP SOL (CIP) SALBUTAMOL
|
SALBUTAMOL
|
ASTHALIN
|
15ML
|
A
|
1.96
|
1.9572
|
BOTT
|
20
|
BOTT
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
48120412
|
SELECTIVE BETA2 ADRENERGIC AGONIST (RESPIRATORY)
|
2024-04-01
|
2026-03-31
|
|
INHALATION
|
6
|
SELECTIVE BETA2 ADRENERGIC AGONIST (RESPIRA
|
|
|
|
|
42
|
0884AJ
|
ASTHALIN 5MG/ML RESP SOL (CIP) SALBUTAMOL
|
SALBUTAMOL
|
ASTHALIN
|
15ML
|
A
|
2.07
|
2.07
|
BOTT
|
20
|
BOTT
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
48120412
|
SELECTIVE BETA2 ADRENERGIC AGONIST (RESPIRATORY)
|
2026-04-01
|
|
|
INHALATION
|
6
|
SELECTIVE BETA2 ADRENERGIC AGONIST (RESPIRA
|
|
|
|
|
40
|
0884BL
|
IPRAVENT 0.25MG/ML RESP SOL (CIP/AHI) IPRATRO
|
IPRATROPIUM BROMIDE
|
IPRAVENT
|
20X2ML
|
A
|
32.70
|
1.64
|
RESPIRATORY
|
1
|
AMP
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
481208
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
2022-04-01
|
2024-03-31
|
|
Nasal
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
40
|
0884BT
|
IPRAVENT 0.25MG/ML RESP SOL (CIP/AHI) IPRATRO
|
IPRATROPIUM BROMIDE
|
IPRAVENT
|
15ML
|
A
|
1.82
|
1.82
|
RESPIRATORY
|
1
|
BOTT
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
481208
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
2022-04-01
|
2024-03-31
|
|
Nasal
|
6
|
RESPIRATORY TRACT AGENTS
|
|
|
|
|
41
|
0884BT
|
IPRAVENT 0.25MG/ML RESP SOL (CIP) IPRATROPIUM
|
IPRATROPIUM
|
IPRAVENT
|
15ML
|
A
|
6.5
|
6.4968
|
BOTT
|
1
|
BOTT
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
481208
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
2024-04-01
|
2026-03-31
|
|
NASAL
|
6
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
|
|
|
|
42
|
09122
|
IPRAVENT 0.25MG/ML RESP SOL (CIP) IPRATROPIUM
|
IPRATROPIUM
|
IPRAVENT
|
15ML
|
A
|
3.23
|
3.23
|
BOTT
|
1
|
BOTT
|
CIP
|
CIPLA LTD
|
|
ARMSTRONG HEALTHCARE INC
|
B
|
481208
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
2026-04-01
|
|
|
ORAL INHALATION
|
6
|
ANTICHOLINERGIC AGENTS (RESPIRATORY)
|
|
|
|
|
40
|
11529
|
GEMFIBROZIL 600MG TAB (CIP/AHI)
|
GEMFIBROZIL
|
GEMFIBROZIL
|
60'S
|
B
|
40.86
|
0.68
|
TABLET
|
60
|
TAB
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
240606
|
FIBRIC ACID DERIVATIVES
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
41
|
11529
|
GEMFIBROZIL 600MG TAB (CIP)
|
GEMFIBROZIL
|
GEMFIBROZIL
|
60'S
|
B
|
40.86
|
0.6809
|
TAB
|
60
|
BOX
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
240606
|
FIBRIC ACID DERIVATIVES
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
FIBRIC ACID DERIVATIVES
|
|
|
|
|
42
|
11529
|
GEMFIBROZIL 600MG TAB (CIP)
|
GEMFIBROZIL
|
GEMFIBROZIL
|
60'S
|
C
|
40.91
|
0.68
|
TAB
|
60
|
BLIS
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
240606
|
FIBRIC ACID DERIVATIVES
|
2026-04-01
|
|
|
ORAL
|
6
|
FIBRIC ACID DERIVATIVES
|
|
|
|
|
40
|
1183G
|
METOPROLOL 1MG/ML INJ (CIP/AHI)
|
METOPROLOL
|
METOPROLOL
|
5X5ML
|
BQ
|
13.21
|
2.64
|
INJECTION
|
0
|
VIAL
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
2424
|
BETA ADRENERGIC BLOCKING AGENTS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
CARDIOVASCULAR DRUGS
|
|
|
|
|
41
|
1183G
|
METOLAR 1MG/ML INJ (CIP) METOPROLOL
|
METOPROLOL
|
METOLAR
|
5X5ML
|
BQ
|
13.21
|
2.6422
|
VIAL
|
0
|
BOX
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
2424
|
BETA ADRENERGIC BLOCKING AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
BETA ADRENERGIC BLOCKING AGENTS
|
|
|
|
|
40
|
2451AF
|
LOPERAMIDE 2MG CAP (CIP/AHI)
|
LOPERAMIDE
|
LOPERAMIDE
|
30X10
|
A
|
27.94
|
0.09
|
CAPSULE
|
30
|
CAP
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
5608
|
ANTIDIARRHEA AGENTS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
GASTROINTESTINAL DRUGS
|
|
|
|
|
40
|
4463N
|
DONEPEZIL 5MG TAB (CIP/AHI)
|
DONEPEZIL
|
DONEPEZIL
|
4X7'S
|
A
|
8.05
|
0.2875
|
TABLET IMMED
|
30
|
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1204
|
PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS
|
2022-11-29
|
2024-03-31
|
Add to Contract as Cat A
|
oral
|
6
|
PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS
|
2022-11-29
|
|
|
|
40
|
4981D
|
DACARBAZINE 200MG INJ (CIP/AHI)
|
DACARBAZINE
|
DACARBAZINE
|
200MG VIAL
|
BQ
|
23.02
|
23.02
|
INJECTION
|
0
|
VIAL
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
5062AB
|
REHYDRATION SALTS (CIP/AHI)
|
REHYDRATION SALTS
|
REHYDRATION SALTS
|
30'S
|
A
|
17.91
|
0.60
|
|
10
|
SACH
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
4012
|
REPLACEMENT THERAPY
|
2022-04-01
|
2024-03-31
|
|
Oral
|
0
|
ELECTROLYTIC, CALORIC, AND WATER BALANCE
|
|
|
|
|
41
|
5062AF
|
PROLYTE ORS PWDR (CIP) REHYDRATION SALTS
|
REHYDRATION SALTS
|
PROLYTE ORS
|
40'S
|
A
|
23.92
|
0.598
|
BOX
|
10
|
SACH
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
4012
|
REPLACEMENT THERAPY
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
0
|
REPLACEMENT THERAPY
|
|
|
|
|
42
|
5062AF
|
PROLYTE ORS PWDR (CIP) REHYDRATION SALTS
|
REHYDRATION SALTS
|
PROLYTE ORS
|
40'S
|
A
|
23.92
|
0.60
|
BOX
|
10
|
SACH
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
4012
|
REPLACEMENT THERAPY
|
2026-04-01
|
|
|
ORAL
|
0
|
REPLACEMENT THERAPY
|
|
|
|
|
40
|
51725
|
ALBENDAZOLE 40MG/ML SUSP (CIP/AHI)
|
ALBENDAZOLE
|
ALBENDAZOLE
|
10ML
|
A
|
1.36
|
0.14
|
SUSPENSION
|
30
|
ML
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
0808
|
ANTHELMINTICS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
1
|
ANTI-INFECTIVE AGENTS
|
|
